J&J Fights Attys' Pursuit Of Confidential Risperdal Docs

Law360, Philadelphia (December 18, 2013, 6:05 PM EST) -- A Johnson & Johnson unit argued in Pennsylvania court Monday that the public release of discovery documents in a slew of state product liability cases, pending as part of a mass tort program, over the antipsychotic drug Risperdal would prejudice the drugmaker.

Janssen Pharmaceuticals Inc. argued that the plaintiffs' counsel were requesting the release of the documents as part of a coordinated smear campaign, according to a brief.

The plaintiffs — whose complaint claims Risperdal caused gynecomastia, or abnormal growth of breast tissue in adolescent boys...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.